These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20169675)

  • 21. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2013 May; 78(95):28735-9. PubMed ID: 23678676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Jun; 75(124):37295-9. PubMed ID: 20608285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Dec; 72(231):67850-2. PubMed ID: 18064769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schedules of controlled substances: removal of naloxegol from control. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2015 Jan; 80(15):3468-70. PubMed ID: 25730920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2014 Aug; 79(167):51243-7. PubMed ID: 25167596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Final order.
    Drug Enforcement Administration. Department of Justice
    Fed Regist; 2013 Nov; 78(221):68716-9. PubMed ID: 24236337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2011 Oct; 76(204):65371-5. PubMed ID: 22016903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr; 65(79):21645-7. PubMed ID: 11010670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schedules of Controlled Substances: Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2015 Sep; 80(176):54715-8. PubMed ID: 26364325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of red phosphorus, white phosphorus and hypophosphorous acid (and its salts) as list I chemicals; exclusions and waivers. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37411-4. PubMed ID: 12836650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Anabolic Steroid Control Act of 2004: a study in the political economy of drug policy.
    Denham BE
    J Health Soc Policy; 2006; 22(2):51-78. PubMed ID: 17255072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Apr; 74(64):15595-625. PubMed ID: 19507319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2014 Aug; 79(163):49661-82. PubMed ID: 25167591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schedules of controlled substances; table of excluded nonnarcotic products: nasal decongestant inhalers manufactured by Classic Pharmaceuticals, LLC. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Mar; 75(55):13678-9. PubMed ID: 20383920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schedules of controlled substances: extension of temporary placement of methylone into schedule I of the Controlled Substances Act. Final order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2012 Oct; 77(202):64032-3. PubMed ID: 23077760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.